Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elacestrant + Abemaciclib in ER+, HER2- Breast Cancer with Brain Metastasis
NCT05386108Phase 2Recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Molecular Glues
- Countries
- 10
01
Overview
A Phase 2 trial of elacestrant in breast cancer, brain metastasis (BM), sponsored by Stemline Therapeutics. Started Aug 2022; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancerbrain metastasis (BM)
Beyond the preview
Go deeper on NCT05386108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386108.